Health Equity Considerations for Children With Type 1 Diabetes Who Utilize Insulin Cost-Sharing Cap Programs
- PMID: 39087202
- PMCID: PMC11290402
- DOI: 10.7759/cureus.63588
Health Equity Considerations for Children With Type 1 Diabetes Who Utilize Insulin Cost-Sharing Cap Programs
Abstract
The cost associated with type 1 diabetes care is considerable and the rising price of insulin has further amplified this financial burden. To curb insulin costs, numerous policies have been enacted in the past five years, both by pharmaceutical companies and their intermediaries, as well as federal and state legislatures. The most notable example is implementation of insulin cost-sharing cap laws, which place limits on out-of-pocket expenses for insulin, and in some cases, diabetes technology. Although insulin cost-sharing cap laws have the potential to mitigate the financial burden associated with routine diabetes care, these policies have largely benefitted adults living with type 1 diabetes, while children, especially those from racial and ethnic underrepresented groups, appear to have derived limited advantage. We describe the current state of insulin cost-sharing cap laws and utilization among children and adolescents with type 1 diabetes, with a focus on the limitations of current insulin laws, the importance of measuring health outcomes for children who utilize such programs, and the impact on health equity. We provide a call to action for policymakers and provide recommendations for future research in this area.
Keywords: diabetes mellitus; healthy equity; medicaid population; public heath; type 1 diabetes.
Copyright © 2024, DeWitt et al.
Conflict of interest statement
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: K.D. and K.R.B. declare no competing interests related to this manuscript. P.B. has received advisory panel, consultancy, or research support from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck, Novo Nordisk, Horizon Pharma / Amgen, and LG Chem. P.B. serves on steering committees for Eli Lilly and Novo Nordisk, and chairs data monitoring committees for Bayer.
References
-
- Biniek JF, Johnson W. Health Care Cost Institute; [ Apr; 2022 ]. 2019. Spending on Individuals With Type 1 Diabetes and the Role of Rapidly Increasing Insulin Prices.
-
- American Diabetes Association; 2023. PBM Policies and Their Impact on Drug and Device Costs.
-
- Text - S.3700 - 117th Congress (2021-2022): Affordable Insulin Now Act. [ Jan; 2023 ]. 2022. https://www.congress.gov/bill/117th-congress/senate-bill/3700/text https://www.congress.gov/bill/117th-congress/senate-bill/3700/text
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous